{"filing":{"accession_number":"0001759425-26-000044","cik":"0001759425","ticker":"MIRM","company_name":"Mirum Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-05","primary_document":"mirm-20260805.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1759425/000175942526000044/mirm-20260805.htm"},"events":[{"id":25240,"run_id":22904,"accession_number":"0001759425-26-000044","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Mirum Pharmaceuticals issued a press release on August 5, 2026, disclosing Q2 2026 financial results, including net product sales of $176.2 million and raising full-year guidance to $680–$700 million. The filing explicitly states this is a disclosure of \"Results of Operations and Financial Condition\" under Item 2.02, with the full press release furnished as Exhibit 99.1. This is a standard earnings release for a quarterly period.","company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":26011,"accession_number":"0001759425-26-000044","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Mirum Pharmaceuticals issued a press release on August 5, 2026, disclosing Q2 2026 financial results, including net product sales of $176.2 million and raising full-year guidance to $680–$700 million. The filing explicitly states this is a disclosure of \"Results of Operations and Financial Condition\" under Item 2.02, with the full press release furnished as Exhibit 99.1. This is a standard earnings release for a quarterly period.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:21:48.899692+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26011,"accession_number":"0001759425-26-000044","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Mirum Pharmaceuticals issued a press release on August 5, 2026, disclosing Q2 2026 financial results, including net product sales of $176.2 million and raising full-year guidance to $680–$700 million. The filing explicitly states this is a disclosure of \"Results of Operations and Financial Condition\" under Item 2.02, with the full press release furnished as Exhibit 99.1. This is a standard earnings release for a quarterly period.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:21:48.899692+00:00","company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","filing_date":"2026-08-05"}]}